Latest Breaking News On - Patient safety card - Page 1 : comparemela.com

Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results

Generated $172.3 million in 1Q 2024 revenues, including $163.1 million in U.S. net product sales $137.5 million for SYFOVRE® $25.6 million for EMPAVELI® Anticipates CHMP opinion for pegcetacoplan.

United statesPhilip ferroneMeredith kayaLissa pavlukCedric francoisExchange commission onApellis pharmaceuticals incAdvisory committee on immunization practicesEuropean unionExchange commissionEuropean medicines agencyNocturnal hemoglobinuriaSenior convertible notesSafety informationRetinal detachmentsRetinal vascular occlusion

VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH

VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesGlasgow cityVoydeyaplus solirisorBart scottMarc dunoyerEuropean hematology associationEuropean unionUniversity of washington medical centerEuropean medicines agencyAlexion pharmaceuticals incDrug administrationDivision of hematologyLancet haematologyWashington medical centerClinical research division

ULTOMIRIS® (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)

First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+ NMOSD the potential to live relapse-free Unprecedented relapse risk reduction observed in CHAMPION-NMOSD trial.

United kingdomNew zealandUnited statesNeuromyelitis opticaHistochem cytochemAlexion pharmaceuticals incDrug administrationParoxysmal nocturnal hemoglobinuriaHemolytic uremic syndromeMyasthenia gravisNeuromyelitis optica spectrum disorderPatient safety cardMitigation strategyPrescribing informationMedication guideNorth america

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

Generated $397 million in full year 2023 revenues, including $275 million for SYFOVRE® and $91 million for EMPAVELI® Strong SYFOVRE launch, with more than 160,000 total doses distributed in 2023.

United statesLissa pavlukCedric francoisMeredith kayaAmerican academy of ophthalmologyExchange commissionApellis pharmaceuticals incAmerican society of nephrologyEuropean unionExchange commission onCommittee for medicinal products human useEuropean medicines agencyAdvisory committee on immunization practicesAmerican society of hematologyRecent business highlightsAmerican academy

ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U S for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive

ZILBRYSQ® is now commercially available by prescription in the United States and dispensed by UCB s selected exclusive specialty pharmacy PANTHERx® Rare Pharmacy.ZILBRYSQ is FDA-approved as the.

Bruxelles capitaleUnited statesJim baxterHoward jf jrLaurent schotsDaphne teoAntje witteDrug administrationBrand communicationsUs communicationsCorporate communicationsGroup of companiesUcb incJamesf myasthenia gravis foundation of americaStudy teamNational institute of neurological disorders